TITLE

A randomized controlled clinical trial of vildagliptin plus metformin combination therapy in patients with type II diabetes mellitus

AUTHOR(S)
YONG SU; YA-LI SU; LI-FANG LV; LI-MIN WANG; QUAN-ZHONG LI; ZHI-GANG ZHAO
PUB. DATE
April 2014
SOURCE
Experimental & Therapeutic Medicine;2014, Vol. 7 Issue 4, p799
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The aim of the present study was to assess the efficacy and safety of vildagliptin plus metformin combination therapy in patients with type II diabetes mellitus. Type II diabetic patients with poor glycemic control following at least three months of metformin treatment were selected and randomized into two groups. Vildagliptin or placebo was administered with metformin. Body weight, fasting blood glucose (FBG), postprandial glucose (PPG), glycated hemoglobin (HbA1c), blood lipid and hepatorenal function levels were analyzed in the patients prior to and 24-weeks after the trial. FBG, PPG and HbA1c levels of the patients in the vildagliptin group significantly decreased following the trial, whereas no statistically significant differences were observed in the various indicators of the placebo group prior to and following the trial. The FBG, PPG and HbA1c levels in the vildagliptin group were significantly lower compared with the placebo group 24-weeks after the trial. Comparisons of body weight, blood lipid and hepatorenal function between the groups prior to and following the trial exhibited no statistically significant differences. Therefore, vildagliptin plus metformin combination therapy effectively reduced FBG, PPG and HbA1c levels in patients with no risk of weight gain or hepatorenal dysfunction.
ACCESSION #
94754521

 

Related Articles

  • Comparison of efficacy and safety of metformin and vildagliptin versus metformin and glimepiride in patients of Type 2 diabetes mellitus. Gullapalli, Harinika; Desai, Savithri // National Journal of Physiology, Pharmacy & Pharmacology;2018, Vol. 8 Issue 4, p521 

    No abstract available.

  • Combination sitagliptin/metformin improved beta cell function, HbA1c. Barzilai, Nir; Grassia, Tara; Kalvaitis, Katie // Endocrine Today;8/10/2008, Vol. 6 Issue 14, p7 

    The article discusses a study which examined the effect of initial combination therapy with sitagliptin and metformin. Patients were randomly assigned to one of five treatment groups. Results showed that the therapy improved blood glucose levels and markers of beta cell function in patients with...

  • Combination of Linagliptin and Metformin for the Treatment of Patients with Type 2 Diabetes. Haak, Thomas // Clinical Medicine Insights: Endocrinology & Diabetes;2015, Issue 8, p1 

    Type 2 diabetes mellitus (T2DM) is a progressive condition requiring long-term treatment. Most patients with T2DM are unable to maintain normoglycemia using metformin alone; thus, combination therapy is a pivotal part of disease management. Addition of the dipeptidyl peptidase-4 inhibitor...

  • Management & prevention of type 2 diabetes. Sattar, Naveed // Diabetes Digest;2015, Vol. 14 Issue 3, p126 

    A review of the article "Early glycaemic control among patients with type 2 diabetes and initial glucose-lowering treatment," by R. W. Thomsen and colleagues, which appeared in the journal "Diabetes, Obesity and Metabolism" in 2015, is presented.

  • Management & prevention of type 2 diabetes. Sattar, Naveed // Diabetes Digest;2015, Vol. 14 Issue 2, p72 

    The article presents abstracts on topics related to type 2 diabetes (T2D) which include the analysis of initial combination therapy, the effect of extent of weight loss on the reversibility of T2D, and the effectiveness of lifestyle-based weight loss for adults with T2D.

  • Updated Review: Improved Glycemic Control with Repaglinide-Metformin in Fixed Combination for Patients with Type 2 Diabetes. Richard III, John W.; Raskin, Philip // Clinical Medicine Insights: Endocrinology & Diabetes;2011, Issue 4, p29 

    As the prevalence of type 2 diabetes continues to rise, new drug therapies will need to be explored to prevent morbidity and mortality associated with diabetes as well as growing health care costs. Type 2 diabetes is characterized by decreased insulin secretion and sensitivity. Numerous oral...

  • Treatment Effects on Measures of Body Composition in the TODAY Clinical Trial. El ghormli, Laure // Diabetes Care;Jun2013, Vol. 36 Issue 6, p1742 

    OBJECTIVE--The Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) trial showed superiority of metformin plus rosiglitazone (M+R) over metformin alone (M), with metformin plus lifestyle (M+L) intermediate in maintaining glycemic control. We report here treatment effects on...

  • Safety and Tolerability of the Treatment of Youth-Onset Type 2 Diabetes.  // Diabetes Care;Jun2013, Vol. 36 Issue 6, p1765 

    OBJECTIVE--Data related to the safety and tolerability of treatments for pediatric type 2 diabetes are limited. The TODAY clinical trial assessed severe adverse events (SAEs) and targeted nonsevere adverse events (AEs) before and after treatment failure, which was the primary outcome (PO)....

  • Increased Circulating Levels of Betatrophin in Newly Diagnosed Type 2 Diabetic Patients. Hao Hu; Wenjun Sun; Shuqin Yu; Xiafei Hong; Weiyun Qian; Bingqian Tang; Dong Wang; Ling Yang; Jifang Wang; Caoming Mao; Libin Zhou; Guoyue Yuan // Diabetes Care;Oct2014, Vol. 37 Issue 10, p2718 

    OBJECTIVE Betatrophin, a newly identified hormone, has been recently characterized as a potent stimulator that increases the production and expansion of insulin-secreting β-cells in mice, but the physiological role of betatrophin remains poorly understood. This study measured for the first...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics